Published in J Neuroinflammation on November 23, 2010
Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health (2011) 1.27
Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. J Neuroinflammation (2016) 1.00
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci (2013) 0.95
Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation. J Neurosci (2013) 0.93
Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. Biomed Res Int (2015) 0.92
NADPH oxidase and neurodegeneration. Curr Neuropharmacol (2012) 0.92
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
Effect of Quercetin in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease. Evid Based Complement Alternat Med (2012) 0.82
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA? Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Proteomic Analysis of the Effect of Korean Red Ginseng in the Striatum of a Parkinson's Disease Mouse Model. PLoS One (2016) 0.77
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Estimation of nuclear population from microtome sections. Anat Rec (1946) 7.21
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med (1999) 4.88
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol (1999) 3.63
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol (2005) 3.58
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation (2004) 2.91
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration (1995) 2.71
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2009) 2.49
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol (2004) 2.45
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience (1997) 2.07
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci (2008) 1.94
Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci (2003) 1.87
Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem (2000) 1.78
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain (2008) 1.77
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res (2001) 1.72
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A (2006) 1.69
Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol (2003) 1.64
The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol (1999) 1.59
Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci (1997) 1.45
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
The discovery and function of COX-2. J Rheumatol Suppl (1997) 1.39
To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci (2005) 1.39
Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology (2010) 1.38
Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 1.38
Ageing, neurodegeneration and Parkinson's disease. Age Ageing (2010) 1.37
Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol (2007) 1.34
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
The dual personality of NO. Trends Pharmacol Sci (2000) 1.33
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 1.32
Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem (1997) 1.32
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res (2003) 1.32
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 1.31
A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol (1994) 1.28
Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol (2000) 1.28
A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience (2009) 1.26
NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging (2009) 1.26
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 1.26
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26
Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology (1999) 1.24
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience (2002) 1.24
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.11
Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation (2005) 1.09
New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev (2005) 1.08
Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol (2002) 1.08
Limitations of current Parkinson's disease therapy. Ann Neurol (2003) 1.07
Inflammation and Parkinson's disease pathogenesis. Mov Disord (2010) 1.05
Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflammation (2009) 1.05
Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem (2005) 1.02
Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis (2008) 1.02
Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res (2005) 1.01
Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends Pharmacol Sci (2009) 0.95
Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol (2002) 0.94
Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res (2009) 0.94
Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci (1998) 0.94
Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci (2005) 0.93
Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J (2003) 0.92
Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia. J Neurosci Res (2001) 0.91
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med (2009) 0.91
Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res (2003) 0.91
Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci (2008) 0.90
Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets (2010) 0.90
NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis (2007) 0.90
Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem (2001) 0.89
Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res Brain Res Rev (2005) 0.89
NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets (2006) 0.88
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev (2007) 0.88
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol (2004) 0.87
A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 0.87
A dual-hit animal model for age-related parkinsonism. Prog Neurobiol (2009) 0.85
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci (2000) 0.85
Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia. Glia (2001) 0.85
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci Res (2007) 0.84
Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol (2007) 0.84
Modulation of PGE(2) and TNFalpha by nitric oxide and LPS-activated RAW 264.7 cells. Cytokine (2002) 0.84
Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sci (2002) 0.84
NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J Neurochem (2009) 0.84
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res (1990) 0.83
The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur J Pharmacol (2008) 0.81
Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol (2006) 0.81
Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurother (2006) 0.81
NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn J Pharmacol (2001) 0.80
Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res (2004) 0.79
Prostaglandin E2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells. FEBS Lett (1997) 0.79
Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. J Neurochem (2005) 1.18
A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener (2011) 1.13
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther (2009) 1.09
Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci U S A (2004) 1.07
Biotelemetric monitoring of brain neurochemistry in conscious rats using microsensors and biosensors. Sensors (Basel) (2009) 0.98
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci (2002) 0.97
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res (2011) 0.95
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci (2013) 0.95
Chitotriosidase in patients with acute ischemic stroke. Eur Neurol (2005) 0.94
Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci U S A (2004) 0.94
Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation. J Neurosci (2013) 0.93
Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci (2005) 0.93
Real-time monitoring of brain tissue oxygen using a miniaturized biotelemetric device implanted in freely moving rats. Anal Chem (2009) 0.93
Endothelial cell-pericyte cocultures induce PLA2 protein expression through activation of PKCalpha and the MAPK/ERK cascade. J Lipid Res (2007) 0.92
Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J (2003) 0.92
A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther (2010) 0.91
Control of the oxygen dependence of an implantable polymer/enzyme composite biosensor for glutamate. Anal Chem (2006) 0.90
Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets (2010) 0.90
Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Curr Aging Sci (2013) 0.90
Oxygen tolerance of an implantable polymer/enzyme composite glutamate biosensor displaying polycation-enhanced substrate sensitivity. Biosens Bioelectron (2006) 0.90
Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res Brain Res Rev (2005) 0.89
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev (2007) 0.88
Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem Neurosci (2013) 0.87
Small molecules interacting with α-synuclein: antiaggregating and cytoprotective properties. Amino Acids (2013) 0.87
Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology (2008) 0.87
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol (2007) 0.86
Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease. Stem Cells (2014) 0.86
NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models. Br J Pharmacol (2009) 0.86
Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. Eur J Pharmacol (2006) 0.85
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury. Br J Pharmacol (2003) 0.84
Novel integrated microdialysis-amperometric system for in vitro detection of dopamine secreted from PC12 cells: design, construction, and validation. Anal Biochem (2008) 0.84
The MPTP mouse model: cues on DA release and neural stem cell restorative role. Parkinsonism Relat Disord (2008) 0.83
MAPKs mediate the activation of cytosolic phospholipase A2 by amyloid beta(25-35) peptide in bovine retina pericytes. Biochim Biophys Acta (2005) 0.82
A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem (2011) 0.81
Simultaneous telemetric monitoring of brain glucose and lactate and motion in freely moving rats. Anal Chem (2013) 0.80
Activation of phospholipase A(2) and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells. Biochim Biophys Acta (2005) 0.80
Effect of growth factors on nuclear and mitochondrial ADP-ribosylation processes during astroglial cell development and aging in culture. Mech Ageing Dev (2002) 0.80
Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res (2011) 0.79
Regulating Wnt signaling: a strategy to prevent neurodegeneration and induce regeneration. J Mol Cell Biol (2014) 0.79
Contributions by a novel edge effect to the permselectivity of an electrosynthesized polymer for microbiosensor applications. Anal Chem (2009) 0.79
Signaling pathways in the nitric oxide and iron-induced dopamine release in the striatum of freely moving rats: role of extracellular Ca2+ and L-type Ca2+ channels. Brain Res (2005) 0.78
Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts. Biochim Biophys Acta (2007) 0.78
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett (2009) 0.78
Multiple sclerosis and anti-Plasmodium falciparum innate immune response. J Neuroimmunol (2007) 0.77
Exposure to a dysfunctional glucocorticoid receptor from early embryonic life programs the resistance to experimental autoimmune encephalomyelitis via nitric oxide-induced immunosuppression. J Immunol (2002) 0.76
High frequency of TNF alleles -238A and -376A in individuals from northern Sardinia. Cytokine (2004) 0.76
Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid. J Ocul Pharmacol Ther (2011) 0.76
Role of endogenous melatonin in the oxidative homeostasis of the extracellular striatal compartment: a microdialysis study in PC12 cells in vitro and in the striatum of freely moving rats. J Pineal Res (2005) 0.76
Electropolymerized phenol derivatives as permselective polymers for biosensor applications. Analyst (2015) 0.76
Cerebellar degeneration-related autoantigen 1 (CDR1) gene expression in Alzheimer's disease. Neurol Sci (2014) 0.75
Apoptotic cell death and amyloid precursor protein signaling in neuroblastoma SH-SY5Y cells. Ann N Y Acad Sci (2004) 0.75
Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. J Pineal Res (2006) 0.75
NF-kB1 gene expression in Down syndrome patients. Neurol Sci (2014) 0.75